Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

NCT07018427 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms
Triple Negative Breast Cancer
HR+, HER2-, Advanced Breast Cancer
Breast Cancer

Interventions

DRUG: Sacituzumab Govitecan Monotherapy or Combination Therapy

Sponsor

Peking University Cancer Hospital & Institute